Dan Rose – CEO
Dan Rose joined LimFlow in August of 2016 with over 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, Dan was VP and General Manager EMEA for Direct Flow Medical, a leading innovator in Transcatheter Valves. Previously, he was VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company with innovative implantable pump systems.
Dan also spent 8 years in leadership roles at Medtronic in the cardiovascular and cardiac surgery groups, including as Director of Marketing for Coronary Vascular EMEA and leading the Vascular Business unit in the Nordic Region. Earlier in his career, Dan cofounded a device company in the diabetes space and worked as an associate in London for a boutique life sciences VC, High Plains Investment Group. Dan has a BA and a MA from the University of Virginia and a MBA from the Darden Business School.
Sophie Humbert – Chief Operations Officer (COO)
Sophie Humbert brings to LimFlow over 15 years of experience in the medtech industry, with a strong track record of bringing innovation from ideation to market. As a driven and structured entrepreneur, she has been CEO and COO of a number of medtech start-ups in the cardiovascular, endovenous and oncology arenas.
Prior to joining LimFlow, Sophie was the COO of ART, an innovative and multicultural company designing bioresorbable stents for cardiovascular applications. She helped the company earn CE mark for their first generation product and also develop the second generation drug coated bioresorbable stent. As CEO of CermaVein, Sophie successfully led the company from an early development stage, through CE marking, and to commercialization in several markets. Earlier in her career, Sophie held R&D leadership positions within Cerma and Bracco Diagnostics. Sophie holds a PhD in Pharmaceutical Sciences from the University of Geneva, a Master’s degree in Management from EM Lyon and a Pharma doctorate from the University Claude Bernard in Lyon.
Thomas Engels – Vice President, Clinical Affairs
Thomas Engels possesses more than 20 years of clinical research experience for pharma, biotech and medical devices, with 15 years in interventional cardiology. Prior to joining LimFlow, Thomas was vice president of clinical affairs for Claret Medical, Micell Technologies and CardioKinetix, taking the companies’ novel devices through trials to achieve CE Mark, European post-marketing safety surveillance, Chinese (CFDA) approval and de novo FDA clearance.
Previously, Thomas was director of clinical research for 10 years at Abbott Vascular, where he managed its global portfolio of interventional cardiology studies. He holds a BS from Louisiana State University and MBA degrees from the Columbia Business School and the Haas School of Business at University of California, Berkeley.
Paul Limmer – Vice President, Finance and Administration
Paul Limmer brings 30 years of expertise in international finance and administration to his role at LimFlow. Prior to joining LimFlow, he led the European finance and administration functions for Direct Flow Medical, a transcatheter heart valve developer.
Previously, Paul spent 17 years at General Electric and GE Capital, holding a variety of positions in Germany, including finance manager of GE Germany Technology, finance manager M&A and chief financial officer of GE Capital Bank. He began his career as an auditor at Cargill Inc. and built his early finance skills at Siemens. Paul is a Chartered Management Accountant (ACMA) and holds Bachelor’s degrees from Leeds Metropolitan University and the Fachhochschule Bremen.
Zachary Woodson – Vice President, Regulatory Affairs and Quality
Zachary has worked in the medical device industry for 18 years with the majority of that time in the cardiovascular space. He has worked extensively in the quality and regulatory space for both large and small companies. Prior to joining LimFlow, Zachary was the Vice President of QA/RA at Claret Medical and helped bring the first cerebral embolic protection device for use during TAVR to the US market via the de novo pathway and an FDA Advisory Committee.
Zachary has spent his Quality and Regulatory career working on innovative therapies such as bifurcated stents, drug-eluting stents to treat coronary artery disease and erectile disfunction (Medtronic), stents with bioabsorbable coatings (Conor Medsystems) and renal denervation for the treatment of hypertension (Medtronic). Zachary is a graduate of Sonoma State University with a Bachelor’s degree in Psychology.
Theo Mastrokostopoulos – Vice President, Sales and Market Development
Theo Mastrokostopoulos joined LimFlow in late 2017 as Vice President of Sales and Market Development and leads the international field team to establish peripheral deep vein arterialization (pDVA) as a primary therapy for “no-option” CLI. He possesses more than 12 years of experience in the medical device space, with a strong track record in commercial leadership roles. He began his medtech career at Medtronic in their European headquarters in Switzerland with roles of increasing responsibility in marketing and sales within the diabetes, surgical technologies and cardiovascular units.
He then joined TriVascular, an early-stage company with a novel endovascular aneurysm repair (EVAR) device, leading the European operations through an initial public offering and eventual acquisition by Endologix. Most recently, he was the chief commercial officer at CAScination, a spin-off from the University of Bern in Switzerland, leading global commercial efforts to launch a CT-guided navigation technology for interventional oncology. Mr. Mastrokostopoulos holds a Master’s in engineering degree in production engineering and management from the Technical University of Crete and an MBA from the London Business School.
Jenny Gaffney – Vice President, Global Reimbursement
Jenny Gaffney brings over 15 years of experience working in the MedTech industry to design and execute global reimbursement strategies to accelerate patient access to critical therapies.
Most recently, Jenny led global health economics, reimbursement and public policy initiatives for Medtronic’s Coronary and Renal Denervation business. In this role, Jenny worked with affiliates across 50+ countries to maintain reimbursement for well-established coronary therapies and ensure access to renal denervation following regulatory approval.
Prior to Medtronic, Jenny was a consultant in the Reimbursement Practice at Avalere Health, a leading strategic advisory company in the U.S. healthcare field. While there, she supported multiple companies to secure U.S. Medicare coverage, codes, and appropriate payment for new and existing therapies.
Jenny received an A.B. from Harvard University and an executive master’s degree in public health and health services administration at the University of Michigan.